Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials

To evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy. Cohort within a clinical trial. Patients included in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Participants were randomly assigned to injections of rani...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Ophthalmology (Rochester, Minn.) Ročník 122; číslo 4; s. 809
Hlavní autoři:	Grunwald, Juan E, Pistilli, Maxwell, Ying, Gui-Shuang, Maguire, Maureen G, Daniel, Ebenezer, Martin, Daniel F
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.04.2015
Témata:	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Cohort Studies Complement C3 - genetics Complement Factor H - genetics Female Fluorescein Angiography Geographic Atrophy - genetics Geographic Atrophy - pathology High-Temperature Requirement A Serine Peptidase 1 Humans Intravitreal Injections Male Photography Polymorphism, Single Nucleotide Proteins - genetics Ranibizumab Serine Endopeptidases - genetics Toll-Like Receptor 3 - genetics Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - genetics
ISSN:	1549-4713, 1549-4713
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	To evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy. Cohort within a clinical trial. Patients included in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Participants were randomly assigned to injections of ranibizumab or bevacizumab and to a 2-year dosing regimen of monthly or pro re nata (PRN) or to monthly for 1 year and PRN the following year. Digital color photographs and fluorescein angiograms at baseline and 1 and 2 years were evaluated for GA, and the total area of GA was measured by 2 graders masked to treatment; differences were adjudicated. Multivariate linear mixed models of the annual change in the square root of the area included baseline demographic, treatment, and ocular characteristics on imaging as candidate risk factors. Geographic atrophy growth rate. Among 1185 participants, 86 (7.3%) had GA at baseline, 120 (10.1%) developed GA during year 1, and 36 (3.0%) developed GA during year 2. Among 194 eyes evaluable for growth, the rate was 0.43 mm/yr (standard error [SE], ±0.03 mm/year). In multivariate analysis, the growth rate was 0.37 mm/year in eyes receiving bevacizumab and 0.49 mm/year in eyes receiving ranibizumab (difference, 0.11 mm/yr; 95% confidence interval [CI], 0.01-0.22; P = 0.03). Growth rate did not differ between eyes treated monthly and PRN (P = 0.85). Eyes with subfoveal choroidal neovascularization (CNV) lesions had a lower growth rate than eyes with nonsubfoveal CNV lesions (difference, 0.12; 95% CI, 0.01-0.22; P = 0.03). Eyes with GA farther from the fovea had higher growth rates by 0.14 (95% CI, 0.01-27) mm/year for every millimeter farther from the fovea. The growth rate was 0.58 mm/year for eyes with predominantly classic lesions, 0.41 mm/year for eyes with minimally classic lesions, and 0.30 mm/year for eyes with occult only lesions (P < 0.01). The growth rate in eyes having a fellow eye with GA was higher by 0.13 mm/year (95% CI, 0.01-0.24; P = 0.03) than in eyes without GA in the fellow eye. Eyes with epiretinal membrane had a higher growth rate than eyes without epiretinal membrane (difference, 0.16; 95% CI, 0.03-0.30; P = 0.02). Geographic atrophy growth depends on several ocular factors. Ranibizumab may accelerate GA growth.
AbstractList	To evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy.PURPOSETo evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy.Cohort within a clinical trial.DESIGNCohort within a clinical trial.Patients included in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).PARTICIPANTSPatients included in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).Participants were randomly assigned to injections of ranibizumab or bevacizumab and to a 2-year dosing regimen of monthly or pro re nata (PRN) or to monthly for 1 year and PRN the following year. Digital color photographs and fluorescein angiograms at baseline and 1 and 2 years were evaluated for GA, and the total area of GA was measured by 2 graders masked to treatment; differences were adjudicated. Multivariate linear mixed models of the annual change in the square root of the area included baseline demographic, treatment, and ocular characteristics on imaging as candidate risk factors.METHODSParticipants were randomly assigned to injections of ranibizumab or bevacizumab and to a 2-year dosing regimen of monthly or pro re nata (PRN) or to monthly for 1 year and PRN the following year. Digital color photographs and fluorescein angiograms at baseline and 1 and 2 years were evaluated for GA, and the total area of GA was measured by 2 graders masked to treatment; differences were adjudicated. Multivariate linear mixed models of the annual change in the square root of the area included baseline demographic, treatment, and ocular characteristics on imaging as candidate risk factors.Geographic atrophy growth rate.MAIN OUTCOME MEASURESGeographic atrophy growth rate.Among 1185 participants, 86 (7.3%) had GA at baseline, 120 (10.1%) developed GA during year 1, and 36 (3.0%) developed GA during year 2. Among 194 eyes evaluable for growth, the rate was 0.43 mm/yr (standard error [SE], ±0.03 mm/year). In multivariate analysis, the growth rate was 0.37 mm/year in eyes receiving bevacizumab and 0.49 mm/year in eyes receiving ranibizumab (difference, 0.11 mm/yr; 95% confidence interval [CI], 0.01-0.22; P = 0.03). Growth rate did not differ between eyes treated monthly and PRN (P = 0.85). Eyes with subfoveal choroidal neovascularization (CNV) lesions had a lower growth rate than eyes with nonsubfoveal CNV lesions (difference, 0.12; 95% CI, 0.01-0.22; P = 0.03). Eyes with GA farther from the fovea had higher growth rates by 0.14 (95% CI, 0.01-27) mm/year for every millimeter farther from the fovea. The growth rate was 0.58 mm/year for eyes with predominantly classic lesions, 0.41 mm/year for eyes with minimally classic lesions, and 0.30 mm/year for eyes with occult only lesions (P < 0.01). The growth rate in eyes having a fellow eye with GA was higher by 0.13 mm/year (95% CI, 0.01-0.24; P = 0.03) than in eyes without GA in the fellow eye. Eyes with epiretinal membrane had a higher growth rate than eyes without epiretinal membrane (difference, 0.16; 95% CI, 0.03-0.30; P = 0.02).RESULTSAmong 1185 participants, 86 (7.3%) had GA at baseline, 120 (10.1%) developed GA during year 1, and 36 (3.0%) developed GA during year 2. Among 194 eyes evaluable for growth, the rate was 0.43 mm/yr (standard error [SE], ±0.03 mm/year). In multivariate analysis, the growth rate was 0.37 mm/year in eyes receiving bevacizumab and 0.49 mm/year in eyes receiving ranibizumab (difference, 0.11 mm/yr; 95% confidence interval [CI], 0.01-0.22; P = 0.03). Growth rate did not differ between eyes treated monthly and PRN (P = 0.85). Eyes with subfoveal choroidal neovascularization (CNV) lesions had a lower growth rate than eyes with nonsubfoveal CNV lesions (difference, 0.12; 95% CI, 0.01-0.22; P = 0.03). Eyes with GA farther from the fovea had higher growth rates by 0.14 (95% CI, 0.01-27) mm/year for every millimeter farther from the fovea. The growth rate was 0.58 mm/year for eyes with predominantly classic lesions, 0.41 mm/year for eyes with minimally classic lesions, and 0.30 mm/year for eyes with occult only lesions (P < 0.01). The growth rate in eyes having a fellow eye with GA was higher by 0.13 mm/year (95% CI, 0.01-0.24; P = 0.03) than in eyes without GA in the fellow eye. Eyes with epiretinal membrane had a higher growth rate than eyes without epiretinal membrane (difference, 0.16; 95% CI, 0.03-0.30; P = 0.02).Geographic atrophy growth depends on several ocular factors. Ranibizumab may accelerate GA growth.CONCLUSIONSGeographic atrophy growth depends on several ocular factors. Ranibizumab may accelerate GA growth. To evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy. Cohort within a clinical trial. Patients included in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). Participants were randomly assigned to injections of ranibizumab or bevacizumab and to a 2-year dosing regimen of monthly or pro re nata (PRN) or to monthly for 1 year and PRN the following year. Digital color photographs and fluorescein angiograms at baseline and 1 and 2 years were evaluated for GA, and the total area of GA was measured by 2 graders masked to treatment; differences were adjudicated. Multivariate linear mixed models of the annual change in the square root of the area included baseline demographic, treatment, and ocular characteristics on imaging as candidate risk factors. Geographic atrophy growth rate. Among 1185 participants, 86 (7.3%) had GA at baseline, 120 (10.1%) developed GA during year 1, and 36 (3.0%) developed GA during year 2. Among 194 eyes evaluable for growth, the rate was 0.43 mm/yr (standard error [SE], ±0.03 mm/year). In multivariate analysis, the growth rate was 0.37 mm/year in eyes receiving bevacizumab and 0.49 mm/year in eyes receiving ranibizumab (difference, 0.11 mm/yr; 95% confidence interval [CI], 0.01-0.22; P = 0.03). Growth rate did not differ between eyes treated monthly and PRN (P = 0.85). Eyes with subfoveal choroidal neovascularization (CNV) lesions had a lower growth rate than eyes with nonsubfoveal CNV lesions (difference, 0.12; 95% CI, 0.01-0.22; P = 0.03). Eyes with GA farther from the fovea had higher growth rates by 0.14 (95% CI, 0.01-27) mm/year for every millimeter farther from the fovea. The growth rate was 0.58 mm/year for eyes with predominantly classic lesions, 0.41 mm/year for eyes with minimally classic lesions, and 0.30 mm/year for eyes with occult only lesions (P < 0.01). The growth rate in eyes having a fellow eye with GA was higher by 0.13 mm/year (95% CI, 0.01-0.24; P = 0.03) than in eyes without GA in the fellow eye. Eyes with epiretinal membrane had a higher growth rate than eyes without epiretinal membrane (difference, 0.16; 95% CI, 0.03-0.30; P = 0.02). Geographic atrophy growth depends on several ocular factors. Ranibizumab may accelerate GA growth.
Author	Pistilli, Maxwell Grunwald, Juan E Martin, Daniel F Ying, Gui-Shuang Daniel, Ebenezer Maguire, Maureen G
Author_xml	– sequence: 1 givenname: Juan E surname: Grunwald fullname: Grunwald, Juan E email: juangrun@mail.med.upenn.edu organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: juangrun@mail.med.upenn.edu – sequence: 2 givenname: Maxwell surname: Pistilli fullname: Pistilli, Maxwell organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 3 givenname: Gui-Shuang surname: Ying fullname: Ying, Gui-Shuang organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 4 givenname: Maureen G surname: Maguire fullname: Maguire, Maureen G organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 5 givenname: Ebenezer surname: Daniel fullname: Daniel, Ebenezer organization: Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania – sequence: 6 givenname: Daniel F surname: Martin fullname: Martin, Daniel F organization: Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25542520$$D View this record in MEDLINE/PubMed
BookMark	eNpNkM1KxDAYRYOMOD_6BiJdumlN0jSdLmXQURhwo-vyJfn6M7RNTVJk3t6KI7g6d3E4i7smi8EOSMgtowmjTD4cEzs2oYGEUyYSxhJK8wuyYpkoYpGzdPFvL8na-yOlVMpUXJElzzLBM05XxOyd_QpNZKuoRls7GJtWRxDcHD9F7RCFBiNt-xFc6-3w40GNscMOApqoBz114CKDNQ7oILSzExxC6HEIfp4tdP6aXFYz8ObMDfl4fnrfvcSHt_3r7vEQ66xgIZYotNRKKM2M2gomDeSa021VGIoq4zlVnKWUSy5VCiytBFNqC1AUW20oR74h97_d0dnPCX0o-9Zr7DoY0E6-ZFJKXkjBilm9O6uT6tGUo2t7cKfy7xn-DeEJatg
CitedBy_id	crossref_primary_10_1016_j_pdpdt_2020_102171 crossref_primary_10_1167_iovs_18_24021 crossref_primary_10_1111_aos_14845 crossref_primary_10_1016_j_ophtha_2015_09_036 crossref_primary_10_1016_j_omtn_2022_04_015 crossref_primary_10_1016_j_oret_2017_09_002 crossref_primary_10_1016_j_ophtha_2019_11_010 crossref_primary_10_1016_j_oret_2016_09_005 crossref_primary_10_1007_s00018_019_03422_9 crossref_primary_10_1038_s41433_021_01688_7 crossref_primary_10_1016_j_ophtha_2020_03_031 crossref_primary_10_1016_j_preteyeres_2015_07_007 crossref_primary_10_1080_02713683_2017_1419572 crossref_primary_10_1001_jamaophthalmol_2020_0437 crossref_primary_10_1159_000520171 crossref_primary_10_1080_17469899_2019_1698948 crossref_primary_10_1038_s41598_022_09642_7 crossref_primary_10_1016_j_ophtha_2017_09_028 crossref_primary_10_1016_j_ajo_2015_09_032 crossref_primary_10_3341_kjo_2018_0081 crossref_primary_10_1155_2016_6971831 crossref_primary_10_1186_s12886_016_0237_x crossref_primary_10_1097_IAE_0000000000003075 crossref_primary_10_1177_2474126417703515 crossref_primary_10_1097_IAE_0000000000004567 crossref_primary_10_1136_bjophthalmol_2019_315055 crossref_primary_10_1097_IAE_0000000000001330 crossref_primary_10_1038_s41433_020_01169_3 crossref_primary_10_1016_j_omtm_2020_03_030 crossref_primary_10_1159_000443209 crossref_primary_10_3389_fmed_2024_1438768 crossref_primary_10_1056_NEJMcp2102061 crossref_primary_10_1007_s00417_015_3260_3 crossref_primary_10_1159_000439358 crossref_primary_10_1016_j_oret_2018_04_009 crossref_primary_10_1097_MD_0000000000011737 crossref_primary_10_1016_j_ophtha_2020_02_009 crossref_primary_10_1097_MD_0000000000006422 crossref_primary_10_1167_iovs_18_26344 crossref_primary_10_1007_s00417_019_04361_8 crossref_primary_10_1016_j_ajo_2018_03_020 crossref_primary_10_1080_02713683_2020_1849730 crossref_primary_10_1136_bjophthalmol_2020_317161 crossref_primary_10_1007_s40123_019_0177_7 crossref_primary_10_1016_j_cytox_2020_100031 crossref_primary_10_1016_S0140_6736_15_00345_1 crossref_primary_10_1038_s41433_022_02221_0 crossref_primary_10_1016_j_ajpath_2018_10_021 crossref_primary_10_1097_IAE_0000000000001457 crossref_primary_10_1097_IAE_0000000000002668 crossref_primary_10_1097_IAE_0000000000002789 crossref_primary_10_1097_ICU_0000000000000259 crossref_primary_10_1097_IAE_0000000000001059 crossref_primary_10_1111_febs_16356 crossref_primary_10_1097_IAE_0000000000002825 crossref_primary_10_1016_j_ajo_2017_12_019 crossref_primary_10_1080_08820538_2019_1701045 crossref_primary_10_1038_s41598_017_09632_0 crossref_primary_10_1016_j_ajo_2016_06_021 crossref_primary_10_1186_s12886_017_0544_x crossref_primary_10_4103_1673_5374_205083 crossref_primary_10_1016_j_exer_2016_10_013 crossref_primary_10_1097_IIO_0000000000000080 crossref_primary_10_1016_j_pdpdt_2024_104028 crossref_primary_10_1016_j_oftale_2017_10_003 crossref_primary_10_3928_23258160_20230223_01 crossref_primary_10_1016_j_oret_2020_11_003 crossref_primary_10_3341_kjo_2017_0079 crossref_primary_10_1016_j_ophtha_2018_11_025 crossref_primary_10_1007_s00347_016_0306_9 crossref_primary_10_3390_biom11050712 crossref_primary_10_4137_OED_S38863 crossref_primary_10_1016_j_ophtha_2018_11_020 crossref_primary_10_1136_bjo_2025_327339 crossref_primary_10_1089_jop_2016_0098 crossref_primary_10_1016_j_ophtha_2019_09_030 crossref_primary_10_1016_j_oret_2023_03_004 crossref_primary_10_1007_s00417_015_3146_4 crossref_primary_10_1097_IAE_0000000000001863 crossref_primary_10_1371_journal_pone_0186272 crossref_primary_10_1038_s41433_023_02439_6 crossref_primary_10_1007_s40123_019_00227_8 crossref_primary_10_1007_s00717_020_00471_5 crossref_primary_10_1007_s40123_016_0047_5 crossref_primary_10_1038_srep26059 crossref_primary_10_1016_j_exer_2021_108518 crossref_primary_10_1097_IAE_0000000000002054 crossref_primary_10_1038_s41433_022_02153_9 crossref_primary_10_1111_cxo_12982 crossref_primary_10_1016_j_oret_2022_04_006 crossref_primary_10_1155_2016_4095852 crossref_primary_10_1136_bjophthalmol_2018_312430 crossref_primary_10_1038_s41467_025_55970_3 crossref_primary_10_1016_j_ajoc_2020_100916 crossref_primary_10_1080_08164622_2024_2361752 crossref_primary_10_1097_IAE_0000000000001117 crossref_primary_10_1517_14712598_2016_1167182 crossref_primary_10_1007_s10384_020_00745_0 crossref_primary_10_1097_IAE_0000000000002842 crossref_primary_10_1097_IAE_0000000000003930 crossref_primary_10_1016_j_ajo_2024_04_018 crossref_primary_10_1016_S0140_6736_22_02609_5 crossref_primary_10_1007_s10456_024_09935_7 crossref_primary_10_1016_j_ophtha_2019_09_008 crossref_primary_10_4103_0301_4738_187659 crossref_primary_10_1111_aos_13157 crossref_primary_10_1016_j_ophtha_2016_12_002 crossref_primary_10_1016_j_ophtha_2019_08_023 crossref_primary_10_1016_j_omtm_2025_101450 crossref_primary_10_1016_j_ophtha_2016_01_034 crossref_primary_10_1016_j_exer_2015_07_016 crossref_primary_10_1016_j_ophtha_2016_01_033 crossref_primary_10_1111_aos_13706 crossref_primary_10_3390_jcto3030014 crossref_primary_10_1097_IAE_0000000000001370 crossref_primary_10_1038_eye_2016_208 crossref_primary_10_1097_IAE_0000000000001133 crossref_primary_10_1136_bjophthalmol_2017_310881 crossref_primary_10_1038_srep42546 crossref_primary_10_1097_IAE_0000000000001765 crossref_primary_10_1136_bjophthalmol_2019_313919 crossref_primary_10_1097_IAE_0000000000001766 crossref_primary_10_1177_11206721211001708 crossref_primary_10_3389_fgeed_2020_594984 crossref_primary_10_1016_j_oret_2018_11_013 crossref_primary_10_2147_OPTH_S501953 crossref_primary_10_1016_j_preteyeres_2016_01_001 crossref_primary_10_1016_j_omtm_2020_01_006 crossref_primary_10_1177_1120672120908718 crossref_primary_10_1007_s11357_019_00138_3 crossref_primary_10_3928_23258160_20160229_04 crossref_primary_10_3390_jcm9061863 crossref_primary_10_1016_j_oret_2025_01_011 crossref_primary_10_1097_IAE_0000000000001383 crossref_primary_10_1016_j_ophtha_2016_09_012 crossref_primary_10_3390_ijms22168387 crossref_primary_10_1016_j_ajo_2015_12_024 crossref_primary_10_1155_2020_4501395 crossref_primary_10_1016_j_phrs_2015_11_027 crossref_primary_10_1097_IAE_0000000000003961 crossref_primary_10_1016_j_cmet_2021_01_011 crossref_primary_10_1517_14740338_2016_1121232 crossref_primary_10_18621_eurj_446300 crossref_primary_10_3928_23258160_20240805_03 crossref_primary_10_3928_23258160_20220914_01 crossref_primary_10_1097_IAE_0000000000001258 crossref_primary_10_1136_bjophthalmol_2015_308065 crossref_primary_10_1016_j_jcjo_2024_05_007 crossref_primary_10_1038_s41433_025_03723_3 crossref_primary_10_1155_2017_7432739 crossref_primary_10_1016_j_oret_2017_08_018 crossref_primary_10_1016_j_toxicon_2023_107170 crossref_primary_10_1177_11206721241229912 crossref_primary_10_1111_aos_13522 crossref_primary_10_1007_s00417_016_3268_3 crossref_primary_10_1097_IAE_0000000000002480 crossref_primary_10_1080_08820538_2021_1883679 crossref_primary_10_1016_j_oftal_2017_07_004 crossref_primary_10_1159_000501724 crossref_primary_10_1371_journal_pone_0232353 crossref_primary_10_1016_j_ajo_2015_08_024 crossref_primary_10_1097_IAE_0000000000002878 crossref_primary_10_1016_j_visres_2017_05_005 crossref_primary_10_1038_s41598_024_51315_0 crossref_primary_10_1159_000530418 crossref_primary_10_1007_s12325_022_02129_x
ContentType	Journal Article
Copyright	Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
CorporateAuthor	Comparison of Age-related Macular Degeneration Treatments Trials Research Group
CorporateAuthor_xml	– name: Comparison of Age-related Macular Degeneration Treatments Trials Research Group
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.ophtha.2014.11.007
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1549-4713
ExternalDocumentID	25542520
Genre	Multicenter Study Comparative Study Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NEI NIH HHS grantid: U10 EY017828 – fundername: NEI NIH HHS grantid: U10 EY017826 – fundername: NEI NIH HHS grantid: U10 EY017823
GroupedDBID	--- --K .1- .55 .FO .GJ 0R~ 123 1B1 1CY 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ACVFH ADCNI ADMUD ADNMO AEFWE AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGQPQ AIGII AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CGR CS3 CUY CVF DU5 EBS ECM EFJIC EFKBS EIF EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NPM NQ- O9- OF- OPF OQ~ P2P R2- RIG ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP 7X8
ID	FETCH-LOGICAL-c591t-6e4c6cb4bc1db8416da7c208f9d0eb5270b21302626b3a13f41bb8aa998cd02e2
IEDL.DBID	7X8
ISICitedReferencesCount	184
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000351710100029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1549-4713
IngestDate	Wed Oct 01 13:39:10 EDT 2025 Mon Jul 21 05:45:48 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Language	English
License	Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c591t-6e4c6cb4bc1db8416da7c208f9d0eb5270b21302626b3a13f41bb8aa998cd02e2
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
PMID	25542520
PQID	1666296419
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1666296419 pubmed_primary_25542520
PublicationCentury	2000
PublicationDate	2015-04-01
PublicationDateYYYYMMDD	2015-04-01
PublicationDate_xml	– month: 04 year: 2015 text: 2015-04-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Ophthalmology (Rochester, Minn.)
PublicationTitleAlternate	Ophthalmology
PublicationYear	2015
SSID	ssj0006634
Score	2.558052
Snippet	To evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy. Cohort within a clinical trial. Patients... To evaluate the growth of geographic atrophy (GA) during anti-vascular endothelial growth factor (VEGF) therapy.PURPOSETo evaluate the growth of geographic...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	809
SubjectTerms	Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Cohort Studies Complement C3 - genetics Complement Factor H - genetics Female Fluorescein Angiography Geographic Atrophy - genetics Geographic Atrophy - pathology High-Temperature Requirement A Serine Peptidase 1 Humans Intravitreal Injections Male Photography Polymorphism, Single Nucleotide Proteins - genetics Ranibizumab Serine Endopeptidases - genetics Toll-Like Receptor 3 - genetics Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - physiology Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy Wet Macular Degeneration - genetics
Title	Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials
URI	https://www.ncbi.nlm.nih.gov/pubmed/25542520 https://www.proquest.com/docview/1666296419
Volume	122
WOSCitedRecordID	wos000351710100029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhKrwXHzaCaEEIWBVh1A6hbZPrvpQFJI4PdzdtIyISGxZEqsxHc533ffPQi5im0qhME_TVqhWBgBsFSCZK5gxkaAKFf57vrPyWjUn0zScRtwq9q0yoVN9IYaSu1i5DeO3nIUYZDezt-Zmxrl2NV2hMYq6fTQlXFanUx-uoXjaepZZcRADI1wb1E65_O7ynle567zUBBeuz6ePPndyfSHzWD7v6-5Q7ZaN5PeNXqxS1ZMsUc2hi2Rvk_gEeF3ndPS0mkzBj2faeri4rjtdFZQ9AupXs4odPeh4WG-8sUAfZM-fZWCmfq21U66dJmzXlE_C6Q6IK-Dh5f7J9YOXGA6SoOaxSbUsVah0gEox0eCTLTgfZsCNyoSCVfCEZ0IglRPBj0bBkr1pUTIpoELIw7JWlEW5phQ0CbStg8IgcNQBVwBSFxCWi65SeKoSy4X-5ehQjuWQham_Kyynx3skqNGCNm86byRIf5BGyP4yR-ePiWbKNuoybI5Ix2L323Oybr-qmfVx4XXFLyOxsNvxdzLJQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Growth+of+geographic+atrophy+in+the+comparison+of+age-related+macular+degeneration+treatments+trials&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Grunwald%2C+Juan+E&rft.au=Pistilli%2C+Maxwell&rft.au=Ying%2C+Gui-Shuang&rft.au=Maguire%2C+Maureen+G&rft.date=2015-04-01&rft.issn=1549-4713&rft.eissn=1549-4713&rft.volume=122&rft.issue=4&rft.spage=809&rft_id=info:doi/10.1016%2Fj.ophtha.2014.11.007&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-4713&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-4713&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-4713&client=summon